Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

1.280 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.280
Bid (Size) 1.200 (5)
Ask (Size) 1.300 (3)
Prev. Close 1.280
Today's Range 1.280 - 1.280
52wk Range 1.230 - 5.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-64.69%
-64.69%
1 Month
-49.00%
-49.00%
3 Month
-69.95%
-69.95%
6 Month
-47.54%
-47.54%
1 Year
-73.66%
-73.66%

More News

Read More
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Gain Therapeutics: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gold Gains 1%; US Consumer Sentiment Falls In June
Via Benzinga
Dear ARM Stock Fans, Mark Your Calendars for June 24
Via InvestorPlace
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Gain Therapeutics (GANX) Stock Down 25% Today?
Via InvestorPlace
Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Public Ventures Discovery Day
From Gain Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.